This Article Full Text (PDF) Other Versions of this Article: AAC.00336-08v1 52/9/3418    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Amsler, K. M. Articles by Bush, K. PubMed PubMed Citation Articles by Amsler, K. M. Articles by Bush, K.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.00336-08
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

In vitro Activity of Ceftobiprole Against Pathogens from Two Phase 3 Complicated Skin and Skin Structure Infection Clinical Trials

Johnson & Johnson Pharmaceutical Research & Development L.L.C., Raritan, New Jersey; and Case Western Reserve Univ. and University Hospitals Case Medical Center, Cleveland, Ohio

^* To whom correspondence should be addressed. Email: kamsler{at}prdus.jnj.com.

	Abstract

In Phase 3 clinical trials for ceftobiprole treatment of complicated skin and skin structure infections, 1219 gram-positive and 276 gram-negative aerobic baseline pathogens were identified. Ceftobiprole inhibited all staphylococcal isolates at MICs 4 µg/ml, including methicillin-resistant strains. Against Enterobacteriaceae and P. aeruginosa, ceftobiprole potency was similar to cefepime.